ArticleJournal of the American Geriatrics Society2021
Attitudes toward deprescribing among adults with heart failure with preserved ejection fraction.
Article in Journal of the American Geriatrics Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Differences in Older Patients' Attitudes Toward Deprescribing at Contextual and Individual Level.Frontiers in public health · 2022Pooled it
- Trial
- Life-Space Mobility in Heart Failure With Preserved Ejection Fraction.Journal of cardiac failure - intersections · 2026Article
- Geriatric Vulnerabilities Among Adults With Heart Failure With Preserved Ejection Fraction: A Cross-Continent Evaluation.JACC. Advances · 2025Article
- Deprescribing strategies in older patients with heart failure.Internal and emergency medicine · 2025Review
- Article
- Comparison of Physical Frailty Assessments in Heart Failure With Preserved Ejection Fraction.JACC. Advances · 2024Article
- "Starting to think that way from the start": approaching deprescribing decision-making for people accessing palliative care - a qualitative exploration of healthcare professionals views.BMC palliative care · 2024Article
- Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape.Heart failure reviews · 2024Review
- Unlocking Deprescribing Potential in Nursing Homes: Insights from a Focus Group Study with Healthcare Professionals.Drugs & aging · 2024Article
- Deprescribing attitudes and predictors among older adults attending geriatric clinics in Kuwait.PloS one · 2024Article
- Practical Incorporation of Stakeholder-Informed Ethics into Research Funding Decisions.Progress in community health partnerships : research, education, and action · 2024Article
- Malnutrition in heart failure with preserved ejection fraction.Journal of the American Geriatrics Society · 2023Article
- Diuretics, SGLT2 inhibitors and falls in older heart failure patients: to prescribe or to deprescribe? A clinical review.European geriatric medicine · 2023Review
- Physician Perspectives on the Use of Beta Blockers in Heart Failure With Preserved Ejection Fraction.The American journal of cardiology · 2023Article
- Geriatric Domains in Patients with Heart Failure with Preserved Ejection Fraction.Cardiology clinics · 2022Review
- N-of-1 trials to facilitate evidence-based deprescribing: Rationale and case study.British journal of clinical pharmacology · 2022Review
- Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach.Current heart failure reports · 2022Review
- Polypharmacy in Older People With Heart Failure: Roles of the Geriatrician and Pharmacist.Cardiac failure review · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
BACKGROUND/
objectivesAttitudes toward deprescribing could vary among subpopulations. We sought to understand patient attitudes toward deprescribing among patients with heart failure with preserved ejection fraction (HFpEF).
designRetrospective cohort study.
settingAcademic medical center in New York City.
participantsConsecutive patients with HFpEF seen in July 2018-December 2019 at a program dedicated to providing care to older adults with HFpEF. MEASUREMENTS: We assessed the prevalence of vulnerabilities outlined in the domain management approach for caring for patients with heart failure and examined data on patient attitudes toward having their medicines deprescribed via the revised Patient Attitudes Toward Deprescribing (rPATD).
resultsAmong 134 patients with HFpEF, median age was 75 (interquartile range 69-82), 60.4% were women, and 35.8% were nonwhite. Almost all patients had polypharmacy (94.0%) and 56.0% had hyperpolypharmacy; multimorbidity (80.6%) and frailty (78.7%) were also common. Overall, 90.3% reported that they would be willing to have one or more of their medicines deprescribed if told it was possible by their doctors; and 26.9% reported that they would like to try stopping one of their medicines to see how they feel without it. Notably, 91.8% of patients reported that they would like to be involved in decisions about their medicines. In bivariate logistic regression, nonwhite participants were less likely to want to try stopping one of their medicines to see how they feel without it (odds ratio 0.25, 95% confidence interval [0.09-0.62], p = 0.005).
conclusionsPatients with HFpEF contend with many vulnerabilities that could prompt consideration for deprescribing. Most patients with HFpEF were amenable to deprescribing. Race may be an important factor that impacts patient attitudes toward deprescribing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.